Recently, a phase I trial (NCT04024761) with six patients (three AML, one MDS, one CML blast crisis, one blastic plasmacytoid dendritic tumor) reported a response in four patients when CIML-NK cells were adoptively transferred after lymphodepleting chemotherapy and IL-2 administration, in a scenario of post-transplant relapse of myeloid disease [261]. The gene discussed is IL2; the disease is acute myeloid leukemia.